Announcements Trials

Browse Landscape

Status

Completed 9 Not yet recruiting 5 Recruiting 4 Unknown 3 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Testicular Neoplasms 1 Stomach Neoplasms 1 Rectal Neoplasms 1 Oropharyngeal Neoplasms 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma, Extranodal NK-T-Cell 1 Lung Neoplasms 1 Fistula 1 Digestive System Diseases 1 Colorectal Neoplasms 1 Colorectal Cancer Metastatic 1 Colonic Neoplasms 1 Anus Neoplasms 1

Interventions

pembrolizumab 29 Carboplatin 27 Specimen Handling 21 durvalumab 20 Pemetrexed 18 Cisplatin 17 Paclitaxel 16 atezolizumab 15 Nivolumab 15 Magnetic Resonance Spectroscopy 15 osimertinib 11 Radiosurgery 11 Radiotherapy 10 Immunoglobulin G 10 Etoposide 10 Docetaxel 10 Disulfides 10 Radiation 9 Taxes 8 Gemcitabine 8 Biopsy 8 Blood Specimen Collection 7 Standard of Care 6 Practice Guidelines as Topic 6 Ipilimumab 6 Surveys and Questionnaires 5 Platinum 5 Bronchoscopy 5 Bevacizumab 5 Ramucirumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Lung Neoplasms × Tomography, X-Ray Computed × Clear all

NCT05117840 2026-04-30

SHIELD

Guardant Health, Inc.

Active not recruiting

12,000 enrolled

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡